MDS Prognostic Scoring: Use IPSS-R, Consider IPSS-M When Available
The IPSS-R (Revised International Prognostic Scoring System) is the required standard for prognostic evaluation in MDS, not an "MDS IPI" which does not exist as a validated scoring system. 1
Primary Recommendation: IPSS-R
The IPSS-R is explicitly mandated by current guidelines as the preferred prognostic tool for MDS 2, 1. This system stratifies patients into five risk categories (Very Low, Low, Intermediate, High, Very High) based on:
- Cytogenetic risk category (very good to very poor)
- Bone marrow blast percentage (≤2%, >2-5%, 5-10%, >10%)
- Hemoglobin level (≥10,8-<10, <8 g/dL)
- Platelet count (≥100,50-<100, <50 × 10⁹/L)
- Absolute neutrophil count (≥0.8, <0.8 × 10⁹/L)
The NCCN 2025 guidelines specifically note that "given its more accurate risk stratification, the IPSS-R categorization is preferred although the other systems also have good value" 2. The ESMO guidelines are even more direct, stating "IPSS-R is required for prognostic evaluation" 1.
Emerging Alternative: IPSS-M
While IPSS-R remains the guideline-mandated standard, the Molecular International Prognostic Scoring System (IPSS-M) represents a significant advancement that incorporates mutations in 31 genes alongside traditional clinical and cytogenetic parameters 3.
Key advantages of IPSS-M:
- Reclassifies 42-46% of patients compared to IPSS-R, with improved prognostic discrimination 4, 3
- Superior predictive accuracy: ROC analysis shows AUC of 0.705 for IPSS-M versus 0.629 for IPSS-R 4
- Identifies high-risk mutations: TP53^multihit^, FLT3 mutations, and MLL^PTD^ predict adverse outcomes, while SF3B1 mutations (modulated by comutation patterns) indicate favorable prognosis 3
- Validated in multiple cohorts: Confirmed in 2,355 US patients 5 and 754 Japanese patients 3
- Applicable to therapy-related and hypoplastic MDS 5
Practical Implementation:
An open-access web calculator is available at https://mds-risk-model.com/ that handles missing values and generates individualized risk scores 6, 3.
Clinical Decision Algorithm
For immediate clinical use:
- Calculate IPSS-R score (required by guidelines) using bone marrow blasts, cytogenetics, and cytopenias
- If molecular testing is available, calculate IPSS-M for enhanced prognostic accuracy
- Use IPSS-R score ≤3.5 versus >3.5 to distinguish intermediate-risk patients who can be managed as lower-risk versus higher-risk 2
Important caveat: Recent data suggests that none of the prognostic scores (IPSS, IPSS-R, or IPSS-M) effectively predict outcomes in patients treated with erythropoiesis-stimulating agents (ESA), and IPSS fails to predict survival in azacitidine-treated patients 7. This highlights that treatment modality influences the predictive value of these scoring systems.
Additional Prognostic Factors
Guidelines recommend adding molecular analysis for specific mutations that provide independent prognostic value 1:
- TP53 mutations in del(5q) MDS
- SF3B1 mutations in patients with <5% blasts
Comorbidity assessment should also be incorporated into overall prognostic evaluation, though the specific indices are referenced separately in guidelines 2.
Why "MDS IPI" Doesn't Exist
There is no validated "MDS International Prognostic Index (IPI)" in the literature. The IPI is a scoring system used for lymphomas, not MDS. The confusion likely stems from the similar acronym structure, but the correct terminology for MDS is IPSS (original), IPSS-R (revised), or IPSS-M (molecular).